AcquisitionOther
Repare Therapeutics Inc. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Repare Therapeutics Inc. -> target · $2.20
The Company’s clinical-stage pipeline includes RP-3467, a Phase 1 Pol q ATPase inhibitor; and RP-1664, a Phase 1 PLK4 inhibitor.
Open source record (SEC) ↗